286 related articles for article (PubMed ID: 32066146)
1. Adverse Effects of Low-Dose Methotrexate: A Randomized Trial.
Solomon DH; Glynn RJ; Karlson EW; Lu F; Corrigan C; Colls J; Xu C; MacFadyen J; Barbhaiya M; Berliner N; Dellaripa PF; Everett BM; Pradhan AD; Hammond SP; Murray M; Rao DA; Ritter SY; Rutherford A; Sparks JA; Stratton J; Suh DH; Tedeschi SK; Vanni KMM; Paynter NP; Ridker PM
Ann Intern Med; 2020 Mar; 172(6):369-380. PubMed ID: 32066146
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary Adverse Events in Patients Receiving Low-Dose Methotrexate in the Randomized, Double-Blind, Placebo-Controlled Cardiovascular Inflammation Reduction Trial.
Sparks JA; Dellaripa PF; Glynn RJ; Paynter NP; Xu C; Ridker PM; Solomon DH
Arthritis Rheumatol; 2020 Dec; 72(12):2065-2071. PubMed ID: 32741143
[TBL] [Abstract][Full Text] [Related]
3. Effect of Low-Dose Methotrexate on eGFR and Kidney Adverse Events: A Randomized Clinical Trial.
Sparks JA; Vanni KMM; Sparks MA; Xu C; Santacroce LM; Glynn RJ; Ridker PM; Solomon DH
J Am Soc Nephrol; 2021 Dec; 32(12):3197-3207. PubMed ID: 34551998
[TBL] [Abstract][Full Text] [Related]
4. Adverse effects related to methotrexate polyglutamate levels: adjudicated results from the cardiovascular inflammation reduction trial.
Xu C; Selhub J; Jacques P; Paynter NP; MacFadyen JG; Glynn RJ; Ridker PM; Solomon DH
Rheumatology (Oxford); 2021 Jun; 60(6):2963-2968. PubMed ID: 34144603
[TBL] [Abstract][Full Text] [Related]
5. Adverse Effects of Low-Dose Methotrexate in a Randomized Double-Blind Placebo-Controlled Trial: Adjudicated Hematologic and Skin Cancer Outcomes in the Cardiovascular Inflammation Reduction Trial.
Vanni KMM; Berliner N; Paynter NP; Glynn RJ; MacFadyen J; Colls J; Lu F; Xu C; Ridker PM; Solomon DH
ACR Open Rheumatol; 2020 Dec; 2(12):697-704. PubMed ID: 33201596
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
[TBL] [Abstract][Full Text] [Related]
7. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study.
van Ede AE; Laan RF; Rood MJ; Huizinga TW; van de Laar MA; van Denderen CJ; Westgeest TA; Romme TC; de Rooij DJ; Jacobs MJ; de Boo TM; van der Wilt GJ; Severens JL; Hartman M; Krabbe PF; Dijkmans BA; Breedveld FC; van de Putte LB
Arthritis Rheum; 2001 Jul; 44(7):1515-24. PubMed ID: 11465701
[TBL] [Abstract][Full Text] [Related]
8. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
[TBL] [Abstract][Full Text] [Related]
9. Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study.
Sparks JA; Barbhaiya M; Karlson EW; Ritter SY; Raychaudhuri S; Corrigan CC; Lu F; Selhub J; Chasman DI; Paynter NP; Ridker PM; Solomon DH
Semin Arthritis Rheum; 2017 Aug; 47(1):133-142. PubMed ID: 28284844
[TBL] [Abstract][Full Text] [Related]
10. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.
Bakker MF; Jacobs JW; Welsing PM; Verstappen SM; Tekstra J; Ton E; Geurts MA; van der Werf JH; van Albada-Kuipers GA; Jahangier-de Veen ZN; van der Veen MJ; Verhoef CM; Lafeber FP; Bijlsma JW;
Ann Intern Med; 2012 Mar; 156(5):329-39. PubMed ID: 22393128
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial.
Zhang X; Miao M; Zhang R; Liu X; Zhao X; Shao M; Liu T; Jin Y; Chen J; Liu H; Zhang X; Li Y; Zhou Y; Yang Y; Li R; Yao H; Liu Y; Li C; Li Y; Ren L; Su Y; Sun X; He J; Li Z
Signal Transduct Target Ther; 2022 Mar; 7(1):67. PubMed ID: 35250032
[TBL] [Abstract][Full Text] [Related]
12. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME
Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial.
Emery P; Fleischmann RM; Strusberg I; Durez P; Nash P; Amante EJ; Churchill M; Park W; Pons-Estel B; Han C; Gathany TA; Xu S; Zhou Y; Leu JH; Hsia EC
Arthritis Care Res (Hoboken); 2016 Jun; 68(6):744-52. PubMed ID: 26474452
[TBL] [Abstract][Full Text] [Related]
14. A Pilot Randomized Controlled Double-Blind Trial of High- Versus Low-Dose Weekly Folic Acid in People With Rheumatoid Arthritis Receiving Methotrexate.
Stamp LK; OʼDonnell JL; Frampton C; Drake J; Zhang M; Barclay M; Chapman PT
J Clin Rheumatol; 2019 Oct; 25(7):284-287. PubMed ID: 30001258
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial.
Braun J; Kästner P; Flaxenberg P; Währisch J; Hanke P; Demary W; von Hinüber U; Rockwitz K; Heitz W; Pichlmeier U; Guimbal-Schmolck C; Brandt A;
Arthritis Rheum; 2008 Jan; 58(1):73-81. PubMed ID: 18163521
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year.
Kremer JM; Blanco R; Brzosko M; Burgos-Vargas R; Halland AM; Vernon E; Ambs P; Fleischmann R
Arthritis Rheum; 2011 Mar; 63(3):609-21. PubMed ID: 21360490
[TBL] [Abstract][Full Text] [Related]
18. Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial.
Reich K; Signorovitch J; Ramakrishnan K; Yu AP; Wu EQ; Gupta SR; Bao Y; Mulani PM
J Am Acad Dermatol; 2010 Dec; 63(6):1011-8. PubMed ID: 20933301
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age.
Tesser J; Kafka S; DeHoratius RJ; Xu S; Hsia EC; Turkiewicz A
Arthritis Res Ther; 2019 Aug; 21(1):190. PubMed ID: 31429794
[TBL] [Abstract][Full Text] [Related]
20. Randomized controlled trial comparing 2 different starting doses of methotrexate in rheumatoid arthritis.
Dhir V; Singla M; Gupta N; Goyal P; Sagar V; Sharma A; Khanna S; Singh S
Clin Ther; 2014 Jul; 36(7):1005-15. PubMed ID: 24976447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
